CERo Therapeutics raises up to $7M via Series E convertible preferred private placement

CERO THERAPEUTICS HOLDINGS, INC.

Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.
Series C and D conversion price reduced to $1.76 as consent for pari passu treatment with Series E.
Company to seek stockholder approval by Oct 31, 2025 for lower conversion; meeting target Dec 31, 2025.
Bankruptcy trigger and company optional redemption each at 25% premium.
Registration rights agreement filed to register resale of conversion shares.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.